From: Government use licenses in Thailand: an assessment of the health and economic impacts
Parameters | USD/yr | References |
---|---|---|
EFV-based ARVs treatment | 1,922 | [44] |
NVP-based ARVs treatment | 3,087 | [44] |
LPV/r-based ARVs treatment | 910 | DMSIC |
IDV/r-based ARVs treatment | 1,210 | DMSIC |
clopidogrel plus aspirin for secondary prevention of ischemic heart disease | 19 | DMSIC |
aspirin alone for secondary prevention of ischemic heart disease | 2 | DMSIC |
letrozole for treatment of breast cancer | 78 | DMSIC |
tamoxifen for treatment of breast cancer | 111 | DMSIC |
docetaxel for treatment of breast cancer | 225 | DMSIC |
paclitaxel for treatment of breast cancer | 1,826 | DMSIC |
docetaxel for treatment of lung cancer | 188 | DMSIC |
pemetrexed for treatment of lung cancer | 5,470 | DMSIC |
erlotinib for treatment of lung cancer | 2,684 | DMSIC |